USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Non-Thermal Plasma Device for Wound Disinfection and Promotion of…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
1248148
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
Sterionics, Inc.
526 S. Main Street #716C Akron, OH 44311-4402
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes
 
Phase 1
Fiscal Year: 2013
Title: SBIR Phase I: Non-Thermal Plasma Device for Wound Disinfection and Promotion of Wound Healing
Agency: NSF
Contract: 1248148
Award Amount: $150,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project is intended to demonstrate the disinfection efficacy of a novel non-thermal-plasma-generating technology that produces a variety of reactive ionic species. Non-thermal plasma discharge has been found to be disruptive to normal bacterial, viral, and spore cell growth and proliferation. Plasma exposure has also been successful at destabilizing biofilms and reducing overall bacterial viability. Phase I work will define the ionic, molecular, and radiation species present in the plasma plume for a wider range of feed gas, and determine which species are most effective at achieving bacterial disinfection, how deep into the infected tissue the plasma plume is effective, and the treatment times necessary to disinfect these tissues. With modifications to the device construction allowing variations in the concentrations of constituents in the feed gas, it is believed that plasmas generated by this device should also impair biofilm formation, destabilize biofilm formation once they mature, and kill large amounts (if not all) of bacteria embedded within the in vitro constructs. With antibiotic resistance and nosocomial infection rates climbing in medical facilities, demonstration of significant germicidal capabilities of non-thermal plasma could be advantageous for patient care. The broader impact/commercial potential of this project is the creation of a unique, portable, and low-cost device that will allow for treatment of wounds without inducing drug-resistance while simultaneously shortening the healing time, thus reducing the treatment cost by 50% or more. This is especially critical for a number of chronic and antibiotic-resistant wounds. The economic and social impact of wound injuries and subsequent infection is immense. The most serious challenge in wound care is treatment of chronic wounds. Chronic wounds affect 6.5 Million people in the US with an estimated $25 billion spent annually on treatment. This number continues to grow due to increasing health care costs, an aging population, and the rise worldwide in the incidence of diabetes and obesity and their associated chronic wounds. The successful development of this technology will have a broad positive impact on patient outcomes.

Principal Investigator:

Stephen P. Weeks
2168818521
spweeks@sterionics.com

Business Contact:

Stephen P. Weeks
2168818521
spweeks@sterionics.com
Small Business Information at Submission:

Sterionics, Inc.
526 S. Main Street #716C Akron, OH 44311-4402

EIN/Tax ID: 263955572
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: Yes